NCT02693535 2026-02-13
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
19 trialsNCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT05257590 2025-12-17
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Recruiting
NCT03505320 2025-10-20
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT04095208 2025-10-02
CONGRATS
Institut Bergonié
Phase 2 Active not recruiting
NCT06463665 2025-09-26
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT03697564 2025-08-06
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
University of California, San Diego
Phase 2 Completed
NCT04350463 2025-01-22
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Celgene
Phase 2 Completed
NCT05655715 2024-10-16
CheckPRO
Herlev and Gentofte Hospital
Phase 2 Completed
NCT03409198 2024-10-15
ICON
Oslo University Hospital
Phase 2 Completed
NCT02664181 2024-09-03
PRECISE
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05964101 2024-05-21
GALAXY-1
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT04300244 2024-02-29
NIPU
Oslo University Hospital
Phase 2 Active not recruiting
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT04984733 2023-11-29
ELEVATE
University of Southampton
Phase 2 Recruiting
NCT02832167 2022-05-09
CheckMate 627
Bristol-Myers Squibb
Phase 2 Completed
NCT03271047 2022-01-04
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Pfizer
Phase 2 Completed
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT02962804 2018-03-05
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
University of Kansas Medical Center
Phase 2 Withdrawn